SCHEMBL5463888

SCHEMBL5463888

O=C(Nc1ccc(Cl)c(Cl)c1)c1c[c]ccc1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 2/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ TBXAS1 P24557 1/20 0.56
▸ PTGS2 P35354 1/20 0.56
▸ MAPK14 Q16539 1/20 0.56
▸ NPC1 O15118 4/20 0.53
▸ RAB9A P51151 4/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ MAPT P10636 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ PKM P14618 1/20 0.53
▸ HDAC3 O15379 1/20 0.51
▸ EGFR P00533 1/20 0.51
▸ HDAC4 P56524 1/20 0.51
▸ HDAC1 Q13547 1/20 0.51
▸ HDAC7 Q8WUI4 1/20 0.51
▸ HDAC2 Q92769 1/20 0.51
▸ HDAC10 Q969S8 1/20 0.51
▸ HDAC11 Q96DB2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5468300 0.84 SNCA (0.56) NPC1RAB9AMEN1KMT2AMAOA
SCHEMBL5469832 0.80 LMNA (0.60) NPC1RAB9AMEN1MAPTKMT2A
SCHEMBL28093056 0.79 PTGS1 (0.72) PTGS1MAPK1TBXAS1PTGS2MAPK14
SCHEMBL5464092 0.79 TOP1 (0.46) MEN1KMT2AKDM4ELMNAP2RX1
SCHEMBL5468406 0.79 KCNMA1 (0.56) MAPK1NPC1RAB9AMEN1MAPT
SCHEMBL5463705 0.78 SRC (0.55) MAPK1NPC1RAB9AMEN1MAPT
SCHEMBL5457651 0.78 KCNQ3 (0.52) RAB9A
SCHEMBL467396 0.78 P2RX1 (0.77) PTGS1MAPK1TBXAS1PTGS2MAPK14
SCHEMBL5468424 0.77 NPC1 (0.56) MAPK1PTGS2NPC1RAB9AMEN1
SCHEMBL5462595 0.77 SMN1; SMN2 (0.59) MAPK1NPC1RAB9AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 — — US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 PTGS1 86/4885MAPK1 256/4885TBXAS1 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback